Schizophrenia study: Acetazolamide
Official title Acetazolamide for Treatment Resistant Schizophrenia
ClinicalTrials.gov ID: NCT04887792
What this study is testing
What is Acetazolamide?
An investigational oral medicine being studied as an adjunctive treatment for schizophrenia. Acetazolamide is designed to inhibit carbonic anhydrase, which can affect brain chemistry and fluid balance.
Also referred to as Diamox.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if adding the drug acetazolamide to standard care improves symptoms in people with treatment-resistant schizophrenia.
- Who it's for
- The study is looking for adults with schizophrenia or schizoaffective disorder whose symptoms have not improved with current medications.
- What's involved
- Participants will take acetazolamide or a placebo (a pill with no active drug) along with their usual medications. They will attend regular visits for check-ups and tests to monitor their health and symptoms.
- Time commitment
- The study duration and specific visit schedule are not provided in the source text.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55
You may be able to join if
- Written informed consent.
- Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
- PANSS total score \> 60 and Score \> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6...
- Stable dose of antipsychotic drug (APD) for \> 1 month, continued throughout the study.
- Not participating in another assigned by chance controlled clinical trial (RCT).
You likely can't join if
- Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal.
- History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
- Pregnancy.
- Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure
- Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
- Intellectual disability as defined in DSM 5.
The study team makes the final eligibility decision.
Where it is enrolling
- Pittsburgh, Pennsylvania, United States
- Bangalore, India
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Pittsburgh, Pennsylvania, United States; Bangalore, India. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.